Relationship between matrix metalloproteinase-2 activity and cystatin C levels in patients with hepatic disease.

[1]  T. Hayakawa,et al.  Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease. , 2008, Liver.

[2]  Young-Chae Chang,et al.  Correlation between plasma levels of matrix metalloproteinase (MMP)‐9 /MMP‐2 ratio and α‐fetoproteins in chronic hepatitis carrying hepatitis B virus , 2004 .

[3]  S. Chu,et al.  Increased cystatin C serum concentrations in patients with hepatic diseases of various severities. , 2004, Clinica chimica acta; international journal of clinical chemistry.

[4]  F. Morel,et al.  Circulating Matrix Metalloproteinases 1, 2, 9 and Their Inhibitors TIMP-1 and TIMP-2 as Serum Markers of Liver Fibrosis in Patients With Chronic Hepatitis C: Comparison With PIIINP and Hyaluronic Acid , 2004, American Journal of Gastroenterology.

[5]  J. Ochieng,et al.  Members of the cystatin superfamily interact with MMP-9 and protect it from autolytic degradation without affecting its gelatinolytic activities. , 2003, Biochimica et biophysica acta.

[6]  Y. Tomino,et al.  Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. , 2002, Kidney international.

[7]  E. Petinaki,et al.  Matrix metalloproteinases and their inhibitors in acute viral hepatitis , 2002, Journal of viral hepatitis.

[8]  T. Hayakawa,et al.  Elevation of serum cystatin C concentrations in patients with chronic liver disease , 2001, European journal of gastroenterology & hepatology.

[9]  S. Brown,et al.  How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact , 2001, BMJ : British Medical Journal.

[10]  H. Kawasaki,et al.  Plasma matrix metalloproteinase-9 (gelatinase B) in patients with hepatocellular carcinoma. , 2000, Research communications in molecular pathology and pharmacology.

[11]  S. Chu,et al.  Significant differences in serum activities of matrix metalloproteinase-2 and -9 between HCV- and HBV-infected patients and carriers. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[12]  T. Seifert,et al.  Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. , 2000, Clinical chemistry.

[13]  P. Timms,et al.  Plasma Levels of Matrix Metalloproteinase-2 (MMP-2) and Tissue Inhibitors of Metalloproteinases-1 and -2 (TIMP-1 and TIMP-2) as Noninvasive Markers of Liver Disease in Chronic Hepatitis C Comparison Using ROC Analysis , 1999, Digestive Diseases and Sciences.

[14]  T. Takahara,et al.  Spatial distribution of tissue inhibitor of metalloproteinase-1 mRNA in chronic liver disease. , 1999, Journal of hepatology.

[15]  J. Kos,et al.  Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  A. Kasahara,et al.  Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response. , 1997, Journal of hepatology.

[17]  H. Saisho,et al.  Elevated plasma levels of matrix metalloproteinase‐9 (92‐kd type IV collagenase/gelatinase B) in hepatocellular carcinoma , 1996, Hepatology.

[18]  M. Mizumoto,et al.  Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential , 1996, Hepatology.

[19]  M. Abrahamson,et al.  Latency of cathepsin B secreted by human colon carcinoma cells is not linked to secretion of cystatin C and is relieved by neutrophil elastase. , 1994, Biochimica et biophysica acta.

[20]  S. Saga,et al.  Clinical evaluation of serum tissue inhibitor of metalloproteinases‐1 levels in patients with liver diseases , 1993, Journal of gastroenterology and hepatology.

[21]  H. Kawasaki,et al.  Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma. , 1993, Clinica chimica acta; international journal of clinical chemistry.

[22]  M. Abrahamson,et al.  Cystatin C and cathepsin B in human colon carcinoma: Expression by cell lines and matrix degradation , 1992, International journal of cancer.

[23]  S. Kobayashi,et al.  Diagnosis of cerebral amyloid angiopathy by enzyme-linked immunosorbent assay of cystatin C in cerebrospinal fluid. , 1991, Stroke.

[24]  Y. Murawaki,et al.  Collagenase and collagenolytic cathepsin in normal and fibrotic rat liver. , 1990, Journal of biochemistry.

[25]  G. Filler,et al.  Cystatin C as a marker of GFR--history, indications, and future research. , 2005, Clinical biochemistry.

[26]  N. Gebbia,et al.  Lysosomal cathepsins B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: potential clinical implications. , 1997, Oncology.

[27]  J. Iredale.  Tissue inhibitors of metalloproteinases in liver fibrosis. , 1997, The international journal of biochemistry & cell biology.

[28]  L. Liotta,et al.  Tumor cell interactions with the extracellular matrix during invasion and metastasis. , 1993, Annual review of cell biology.

[29]  L. Matrisian,et al.  Metalloproteinases and their inhibitors in matrix remodeling. , 1990, Trends in genetics : TIG.